Clinical evaluation of estramustine phosphate and vinblastine in patients with hormone-refractory prostate cancer

Acta Urologica Japonica

Volumn 46, Issue 7, 2000, Pages 449-452

  Awakura, Yasuo ^a   Yamamoto, Masakazu ^a   Fukuzawa, Shigeki ^a   Itoh, Noriyuki ^a   Nonomura, Mitsuo ^a   Fukuyama, Takuo ^a  

^a NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

Author keywords

Estramustine phosphate; Hormone refractory; Prostatic cancer; Vinblastine

Indexed keywords

ESTRAMUSTINE PHOSPHATE; PROSTATE SPECIFIC ANTIGEN; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; LYMPH NODE METASTASIS; MALE; PROSTATE CANCER; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESTRAMUSTINE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE;

EID: 0033856781     PISSN: 00181994     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Eisenberger MA: Chemotherapy for hormone-resistant prostate cancer. In: Campbell's Urology. Edited by Walsh PC, Retik AB, Vaughan ED, et al.: 7th ed., pp. 2645-2658, W.B. Saunders Company, Philadelphia, 1998
2. Smith DC: Chemotherapy for hormone refractory prostate cancer. Urol Clin North Am 26: 323-331, 1999
3. Soloway MS, Hardem SW, Hickey D, et al.: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61: 195-202, 1988
4. Gunnarsson PO, Davidsson T, Andersson SB, et al.: Impairment of estramustine phosphate absorption by concurrent intake of milk and food. Eur J Clin Pharmacol 38: 189-193, 1990
5. Gunnarsson PO and Forshell GP: Clinical pharmacokinetics of estramustine phosphate. Urology 23(Suppl): 22-27, 1984
6. Norlen BJ, Andersson SB, Bjork P, et al.: Uptake of estramustine phosphate (estracyt) metabolites in prostatic cancer. J Urol 140: 1058-1062, 1988
7. Bergenheim AT and Hennksson R: Pharmacokinetics and pharmacodynamics of estramustine phosphate. Clin Pharmacokinet 34: 163-172, 1998
8. Liang N, Dahllof B, Hartley-Asp B, et al.: Interaction of estramustine with tubulin isotypes. Biochemistry 36: 871-878, 1997
9. 1 mouse cells and on DU-145 human prostate carcinoma cells in vitro. Cancer Res 48: 1842-1849, 1988
10. Speicher LA, Sheridan VR, Godwin AK, et al.: Resistance to the antimiotic drug estramustine is distinct from the multidrug resistant phenotype. Br J Cancer 64: 267-273, 1991
11. Hudes GR, Greenberg R, Krigel RL, et al.: Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol 10: 1754-1761, 1992
12. Seidman AD, Sher HI, Petrylak D, et al.: Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostate cancer. J Urol 147: 931-934, 1992
13. Amato RJ, Ellerhost J, Bui C, et al.: Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate. Urol Oncol 1: 168-172, 1995
14. Sher HI, Steineck G and Kelly WK: Hormone-refractory (D3) prostate cancer: refining the concept. Urology 46: 142-148, 1995
15. Reese DM and Small EJ: Secondary hormonal manipulations in hormone refractory prostate cancer. Urol Clin North Am 26: 311-321, 1999
16. Smith DC, Dunn RL, Strawderman MS, et al.: Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 16: 1835-1843, 1998
17. Scher HI, Kelly WMK, Zhang ZF, et al.: Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst 91: 244-251, 1999